Atsena Therapeutics has announced positive clinical results from the LIGHTHOUSE study, evaluating subretinal injection of a novel gene therapy to treat X-linked retinoschisis (XLRS).
A research initiative between RMIT University and digital health company DDM Health will look to the potential of artificial intelligence (AI) voice analysis technology
The “first and only” continuous delivery treatment for diabetic retinopathy (DR) has been approved by the United States Food and Drug Administration (US FDA).
The optical industry came together to celebrate outstanding achievement and innovation at the ODMA Awards 2025, with winners announced during a special presentation at
DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.
